Stocks & Investing
Stocks and InvestingStocks and Investing 
Thu, June 18, 2009
Wed, June 17, 2009
BMI, SVNT, GENZ, TNDM, NFLX, EW. Top Gainers With Lowest Price Friction In Morning Trade Today
June 17, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 17, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This fair market making requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the top companies with the largest gains this morning and lowest price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Badger Meter (NYSE: BMI), Savient Pharmaceuticals (NASDAQ: SVNT), Genzyme (NASDAQ: GENZ), Neutral Tandem (NASDAQ: TNDM), NetFlix (NASDAQ: NFLX) and Edwards Lifesciences (NYSE: EW). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction
BMI $3.60 9.14% 23,447 35.11% 19,228 28.79% 4,219 12
SVNT $2.76 29.77% 3,392,022 48.67% 3,383,912 48.56% 8,110 29
GENZ $2.15 4.08% 476,282 50.65% 449,623 47.81% 26,659 124
TNDM $1.93 7.95% 200,074 56.91% 129,751 36.91% 70,323 364
NFLX $1.92 5.08% 245,255 57.96% 175,635 41.51% 69,620 363
EW $1.77 2.76% 37,300 44.90% 31,826 38.31% 5,474 31
Click here to view chart: 
Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows BMI with a dollar gain today of +$3.60 and a Friction Factor of 12 shares. That means that it only took 12 more shares of buying than selling to move BMI higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
Badger Meter, Inc. (NYSE: BMI) engages in manufacturing and marketing flow measurement and control products for water utilities, municipalities, and industrial customers worldwide. Its products are used to measure and control the flow of liquids in various applications. The company provides utility and industrial product lines. The utility product line comprises residential and commercial water meters with various automatic meter reading technology systems. The industrial product line consists of precision valves, electromagnetic inductive flow meters, impeller flow meters, turbine and positive displacement industrial flow meters, and automotive fluid meters. Badger Meter, Inc. sells its products through direct sales representatives, distributors, and independent sales representatives. The company was founded in 1905 and is based in Milwaukee, Wisconsin.
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers. The company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey.
Genzyme Corporation (NASDAQ: GENZ) operates as a biotechnology company worldwide. The company�s Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and Type 3 Gaucher diseases; Fabrazyme, a recombinant form of the human enzyme alpha- galactosidase for the treatment of Fabry disease; Myozyme as a therapy for Pompe disease; and Aldurazyme for the treatment of Mucopolysaccharidosis I. This segment markets and sells its products directly to physicians, hospitals, treatment centers, pharmacies, and government agencies through distributors. Its Cardiometabolic and Renal segment develops, manufactures, and distributes products consisting of Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol, a line of vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer. This segment sells its products to retail pharmacies, hospitals, and other providers of medication to patients. The company�s Biosurgery segment provides biotherapeutics and biomaterial-based products, which comprise Synvisc, a biomaterial-based product that is used to treat the pain associated with osteoarthritis of the knee; and Sepra family of products to prevent adhesions following various surgical procedures in the abdomen and pelvis. Its Hematologic Oncology segment develops products for the treatment of cancer, which include Campath for the treatment of B-cell chronic lymphocytic leukemia; Clolar for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia; and Mozobil for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The company was founded in 1981 and is based in Cambridge, Massachusetts.
Neutral Tandem, Inc. (NASDAQ: TNDM), through its subsidiaries, provides tandem interconnection services principally to competitive carriers, including wireless, wireline, cable, and broadband telephony companies in the United States. Its services enable competitive carriers to interconnect and exchange local and long distance traffic between their networks without establishing direct switch-to-switch connections. The company manages network capacity between its tandem switches and customers� switches, which results in network quality and reduced call blocking. Its network automatically switches Internet protocol (IP)-originated or conventional time division multiplexing (TDM) traffic to terminating carriers, using either protocol. The company supports IP-to-IP, IP-to-TDM, TDM-to-IP, and TDM-to-TDM traffic with protocol conversion and gateway functionality. Neutral Tandem also provides its customers with invoices, management reports, and call detail records in paper and electronic formats along monthly savings summary reports. As of December 31, 2008, its network connected 1,336 competitive carrier switches, creating approximately 1.9 million switch-to-switch routes serving approximately 391 million telephone numbers assigned to these carriers. The company was founded in 2001 and is headquartered in Chicago, Illinois.
Netflix, Inc. (NASDAQ: NFLX) provides online movie rental subscription services in the United States. The company offers its subscribers access to a library of movie, television, and other filmed entertainment titles on digital versatile disc (DVD). Its members can get DVDs delivered to their homes and can instantly watch movies and TV episodes streamed to their TVs and PCs. As of December 31, 2008, Netflix served approximately 10 million subscribers with approximately 100,000 DVD and Blu-ray titles, and a library of 12,000 choices. It also partners with consumer electronics companies to offer a range of devices that can instantly stream movies and TV episodes to members' TVs from Netflix. The company was founded in 1997 and is headquartered in Los Gatos, California.
Edwards Lifesciences Corporation (NYSE: EW) provides products and technologies designed to treat cardiovascular diseases. It focuses primarily on heart valve disease, peripheral vascular disease, and critical care technologies. The company offers tissue heart valves, such as pericardial and porcine valves, as well as repair products, including annuloplasty rings and systems, which are used to replace or repair a patient�s diseased or defective heart valve. It also provides hemodynamic monitoring equipment that is used to measure a patient�s heart function in surgical and intensive care settings; and disposable pressure transducers, and central venous access products for fluid and drug delivery. In addition, the company offers cardiac surgery system products, including cannula, intra-aortic filtration systems, and other disposable products used during cardiopulmonary bypass procedures; and vascular products that include balloon-tipped and catheter-based embolectomy products, surgical clips and clamps, and balloon-expandable and self-expanding non-coronary stents used in the treatment of peripheral vascular disease. Edwards Lifesciences distributes its products through a direct sales force and independent distributors worldwide. It has a collaboration agreement with DexCom, Inc. to develop products for continuously monitoring blood glucose levels in patients hospitalized for various conditions. The company was founded in 1999 and is headquartered in Irvine, California. Edwards Lifesciences Corp. (NYSE:EW) operates independently of Baxter International Inc. as of March 31, 2000.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,550,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net